SUPN Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 13.07%. Supernus Pharmaceuticals's return on equity of 6.24% beat Corcept Therapeutics's return on equity of 21.3%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 23.02%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 93.68%. Given that Corcept Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Supernus Pharmaceuticals's net income of -$11.8M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 28.41x while Corcept Therapeutics's PE ratio is 61.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 12.08x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.68%. Supernus Pharmaceuticals's return on equity of 6.24% beat Eli Lilly and's return on equity of 78.25%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 23.02%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 30.63%. Given that Eli Lilly and has higher upside potential than Supernus Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 28.41x while Eli Lilly and's PE ratio is 61.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 13.85x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.63%. Supernus Pharmaceuticals's return on equity of 6.24% beat Pfizer's return on equity of 8.72%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 23.02%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 27.33%. Given that Pfizer has higher upside potential than Supernus Pharmaceuticals, analysts believe Pfizer is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.36% to investors and pays a quarterly dividend of $0.43 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Pfizer quarterly revenues of $13.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Pfizer's net income of $3B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 28.41x while Pfizer's PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 28.42%. Supernus Pharmaceuticals's return on equity of 6.24% beat Zoetis's return on equity of 51.03%.

Supernus Pharmaceuticals has a consensus price target of $38.80, signalling upside risk potential of 23.02%. On the other hand Zoetis has an analysts' consensus of $194.12 which suggests that it could grow by 19.79%. Given that Supernus Pharmaceuticals has higher upside potential than Zoetis, analysts believe Supernus Pharmaceuticals is more attractive than Zoetis.

Supernus Pharmaceuticals has a beta of 0.736, which suggesting that the stock is 26.408% less volatile than S&P 500. In comparison Zoetis has a beta of 0.942, suggesting its less volatile than the S&P 500 by 5.835%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.15% to investors and pays a quarterly dividend of $0.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Zoetis pays out 31.62% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Zoetis quarterly revenues of $2.2B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Zoetis's net income of $631M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 28.41x while Zoetis's PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.64x versus 7.87x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.